Metagenomi, Inc. (MGX) AI Stock Analysis

Metagenomi, Inc. is an Emeryville, California-based genetic medicines company focused on developing therapeutics through a metagenomics-derived genome editing toolbox. Its technologies encompass programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing and clustered regularly interspaced short palindromic repeat-associated transposases. To advance its pipeline, Metagenomi has established strategic partnerships. These include a collaboration with Affini-T Therapeutics, Inc. to advance gene-edited T-cell receptor-based therapeutics for cancer, as well as an agreement with Ionis Pharmaceuticals, Inc. to co-develop investigational medicines leveraging genome editing technologies.

Metagenomi's revenue expanded from $243,000 in FY2021 to a peak of $52.3M in FY2024 before falling 51.8% to $25.2M in FY2025. This yields a 4-year revenue CAGR of 219.1%. Gross margin stood at 78.9% in FY2025, while operating margin was -380.9%, weighed down by $94.4M in research and development expenses. Net loss widened to -$87.9M in FY2025, or -$2.14 per share. For the trailing twelve months ended June 30, 2026, revenue stood at $13.6M, with quarterly revenue falling 69.8% year-over-year.

As of June 30, 2026, Metagenomi held $120.7M in cash and short-term investments against $37.7M in total debt, resulting in net cash of $82.9M. Total assets were $173.7M against shareholders' equity of $112.6M, supporting a current ratio of 4.50 and a debt-to-equity ratio of 0.34. The company remains cash-flow negative, with operating cash flow of -$88.9M and free cash flow of -$89.5M in FY2025. Capital expenditures totaled $574,000 in FY2025, while the share count increased 1155.3% over five years.

At a last close of $0.78, Metagenomi trades at a market cap of $29.6M and an enterprise value of -$40.1M. Its price-to-sales multiple is 2.2x, below the 4.1x median of its US-listed Healthcare peers. The stock trades at a price-to-book ratio of 0.4x and an EV-to-revenue ratio of 0.7x. Over the past year, MGX shares fell 76.5%, underperforming the S&P 500 (SPY), which gained 16.8%.

Wall Street coverage consists of 4 Strong Buy ratings and 1 Hold rating. The mean price target is $7.00, representing a 792.9% premium over the last close of $0.78. For the fiscal year ending December 31, 2026, analysts estimate revenue of $5.1M and an EPS of -$2.42. For the following fiscal year, 4 analysts project revenue to rise 46.1% to $7.5M, with EPS improving to -$1.83. The company recorded 0 EPS beats over the last 4 quarters, and its next earnings date is November 10, 2026.

This page is an AI-written research summary of Metagenomi, Inc. (MGX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MGX income statement, MGX balance sheet, MGX key metrics, MGX analyst forecast, MGX chart. See the MGX stock overview for the latest quote and news.